According to the latest report by IMARC Group, titled “Hydroxychloroquine Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025”, the . Hydroxychloroquine (HCQ), with the chemical formula C18H26ClN3O, is a chemotherapeutic agent drug mainly used to prevent and treat malaria. It works against the erythrocytic forms of malarial parasites and is often consumed in an oral tablet form. Hydroxychloroquine also treats several other diseases, including systemic lupus erythematosus, rheumatoid arthritis, Q fever, and Porphyria Cutanea Tarda (PCT). In recent times, it is also being tested for the possible treatment of the highly-infectious respiratory disease caused by SARS-CoV-2 virus. Hydroxychloroquine exhibits several immunosuppressive, anti-autophagy, and antimalarial properties since it suppresses immune functions and introduces antigens and cytokines in the body.
Request Free Sample Report: https://www.imarcgroup.com/hydroxychloroquine-market/requestsample
The sudden outbreak of the COVID-19 pandemic, along with the unavailability of a vaccine for mitigating the growth of SARS-CoV-2 virus, is currently driving the demand for hydroxychloroquine. Numerous clinical trials and experiments are being performed to speculate its efficacy and safety to treat coronavirus patients. Furthermore, the growing incidences of malaria and various other chronic diseases, particularly in developing and underdeveloped countries, are also propelling the adoption of this drug. Moreover, the increasing cases of numerous autoimmune diseases, such as lupus erythematosus and rheumatoid arthritis, are further inducing the product demand. Additionally, the deployment of favorable government policies to encourage global health, along with increasing investments in several R&D activities in the field of medical sciences, are expected to drive the global hydroxychloroquine market. Looking forward, IMARC Group expects the global hydroxychloroquine market to experience robust growth during the next five years.
Breakup by Dosage Type:
- 200 Mg
- 300 Mg
- 400 Mg
- Others
Breakup by Distribution:
- Hospital Pharmacies
- Retail Pharmacies
- Others
Breakup by Application:
- Rheumatoid Arthritis
- Lupus Erythematosus
- Malaria
- Coronavirus (COVID-19)
- Others
Breakup by Grade:
- USP Standards Grade
- EP Standards Grade
- Pharmaceutical Standards Grade
- Others
Breakup by Route of Administration:
- Oral
- Intravenous
Breakup by Region:
- North America
- United States
- Canada
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
Competitive Landscape Key Player:
- Amneal Pharmaceuticals Inc.
- Cardinal Health Inc.
- Cipla Ltd.
- Ipca Laboratories Ltd.
- Laurus Labs
- Lupin Limited
- Mylan N.V.
- Novartis AG
- Prasco Laboratories
- Reddy’s Laboratories Ltd.
- Sanofi S.A.
- Teva Pharmaceutical Industries Ltd.
- Torrent Pharma
- Zydus Cadila
Explore Full Report with TOC & List of Figure:
As the novel coronavirus (COVID-19) crisis takes over the world, we are continuously tracking the changes in the markets, as well as the industry behaviours of the consumers globally and our estimates about the latest market trends and forecasts are being done after considering the impact of this pandemic.
Single User: https://www.imarcgroup.com/checkout?id=2266&method=1
Corporate User: https://www.imarcgroup.com/checkout?id=2266&method=3
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact Us
IMARC Group
30 N Gould St Ste R
Sheridan, WY 82801 USA
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800 |
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800
